Last update 01 Nov 2024

Adenovirus Infections, Human

Last update 01 Nov 2024

Basic Info

Synonyms

Adenovirus Infection, Human, Adenovirus Infections, Human, Human Adenovirus Infection

+ [12]

Introduction

Respiratory and conjunctival infections caused by 33 identified serotypes of human adenoviruses.

Drugs associated with Adenovirus Infections, Human

Adenovirus Type 4 and Type 7 Vaccine, Live, Oral(Barr Laboratories, Inc.)

Target-

Mechanism

Immunostimulants

Active Org.

Barr Laboratories, Inc. [+1]

Originator Org.

Barr Laboratories, Inc.

Active Indication

Adenovirus Infections, Human

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date16 Mar 2011

LynVir AB

Target-

Mechanism-

Active Org.

Shanghai Saiao Biotechnology Co. Ltd.

Originator Org.

Shanghai Saiao Biotechnology Co. Ltd.

Active Indication

Adenovirus Infections, Human [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

AdVLP-7

Target-

Mechanism-

Active Org.

TechnoVax, Inc.

Originator Org.

TechnoVax, Inc.

Active Indication

Adenovirus Infections, Human

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Adenovirus Infections, Human

EUCTR2022-002955-20-IT / Unknown statusPhase 3IIT

Double-blind randomized controlled study versus placebo to evaluate the efficacy of mono-administration of betamethasone in children with symptomatic Adenovirus infection (ADENO-beta). - ADENO-beta

Start Date22 Nov 2023

Sponsor / Collaborator-

EUCTR2021-003450-22-SE / Not yet recruitingPhase 3

Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Start Date08 Mar 2022

Sponsor / Collaborator

AlloVir, Inc.

EUCTR2021-003450-22-ES / Not yet recruitingPhase 3

Start Date11 Feb 2022

Sponsor / Collaborator

AlloVir, Inc.

100 Clinical Results associated with Adenovirus Infections, Human

100 Translational Medicine associated with Adenovirus Infections, Human

0 Patents (Medical) associated with Adenovirus Infections, Human

244

Literatures (Medical) associated with Adenovirus Infections, Human

31 Dec 2024·Emerging Microbes & Infections

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews

Article

Author: Wu, Weixuan ; Liu, Yutong ; Li, Zhengfeng ; He, Jun ; Zhang, Xiaoyan ; Qu, Linbing ; Feng, Ying ; Chen, Ling ; Zhou, Rong ; Li, Xiao ; Liu, Xinglong ; Sun, Xikui ; Ye, Xianmiao ; Wang, Nana ; Zhou, Zhichao ; Feng, Liqiang ; Su, Wan ; Zheng, Yali ; Liu, Wenkuan ; Wang, Wei

Re-emerging human adenovirus type 55 (HAdV55) has become a significant threat to public health due to its widespread circulation and the association with severe pneumonia, but an effective anti-HAdV55 agent remains unavailable. Herein, we report the generation of macaque-derived, human-like monoclonal antibodies (mAbs) protecting against HAdV55 infection with high potency. Using fluorophore-labelled HAdV55 virions as probes, we isolated specific memory B cells from rhesus macaques (Macaca mulatta) that were immunized twice with an experimental vaccine based on E1-, E3-deleted, replication-incompetent HAdV55. We cloned a total of 19 neutralizing mAbs, nine of which showed half-maximal inhibitory concentrations below 1.0 ng/ml. These mAbs recognized the hyper-variable-region (HVR) 1, 2, or 7 of viral hexon protein, or the fibre knob. In transgenic mice expressing human desmoglein-2, the major cellular receptor for HAdV55, a single intraperitoneal injection with hexon-targeting mAbs efficiently prevented HAdV55 infection, and mAb 29C12 showed protection at a dose as low as 0.004 mg/kg. Fibre-targeting mAb 28E8, however, showed protection only at a dose up to 12.5 mg/kg. In tree shrews that are permissive for HAdV55 infection and disease, mAb 29C12 effectively prevented HAdV55-caused pneumonia. Further analysis revealed that fibre-targeting mAbs blocked the attachment of HAdV55 to host cells, whereas hexon-targeting mAbs, regardless of their targeting HVRs, mainly functioned at post-attachment stage via inhibiting viral endosomal escape. Our results indicate that hexon-targeting mAbs have great anti-HAdV55 activities and warrant pre-clinical and clinical evaluation.

11 Dec 2024·Journal of Biomolecular Structure and Dynamics

Computational insights into pediatric adenovirus inhibitors: in silico strategies for drug repurposing

Article

Author: Sarkar, Kaushik ; Nandi, Subrata ; Das, Rajesh Kumar

Human adenovirus (HADV) infection can pose a serious threat to children, leading to a variety of respiratory illnesses and other complications. Particularly, children with weak immune systems are vulnerable to severe adenovirus infections with high mortality. The main focus of this study is to propose new antiviral agents as lead HADV inhibitors for children. So, several antiviral agents used in children were subjected to finding new HADV inhibitors using important computational methods of molecular docking, molecular dynamics (MD) simulation, Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) binding free energy calculations, density functional theory (DFT), and pharmacokinetic analysis. Molecular docking of standard cidofovir along with other ligands, suggested that sofosbuvir has the highest binding energy (-10.8 kcal/mol), followed by baloxavir marboxil (-10.36 kcal/mol). Further, the analysis of molecular interactions using MD simulation (100 ns) and MM-PBSA indicated that baloxavir marboxil has formed the most stable protein-ligand complex with HADV, followed by sofosbuvir. The binding free energies of baloxavir marboxil and sofosbuvir were found to be -61.724 kJ/mol and -48.123 kJ/mol, respectively. The DFT and drug-likeness properties of these compounds were also investigated. Overall, two antiviral agents, such as baloxavir marboxil, and sofosbuvir are suggested as lead repurposed candidates against HADV.Communicated by Ramaswamy H. Sarma.

01 Oct 2024·Mucosal Immunology

PD1+CD4+ T cells promote receptor editing and suppress autoreactivity of CD19+CD21low B cells within the lower respiratory airways in adenovirus pneumonia

Article

Author: Zhang, Yanfang ; Yi, Weijing ; Zhang, Fen ; Zhang, Yuxia ; Lu, Bingtai ; Liu, Ming ; Yang, Diyuan ; Lu, Gen ; Fan, Huifeng ; Liu, Wei ; Tang, Jue ; Cai, Li ; Ma, Liuheyi ; Liang, Yufeng ; Nie, Junli ; Wang, Jun ; Rosa Duque, Jaime S ; Zhang, Li ; Gu, Xiaoqiong ; Xu, Yingyi ; Zeng, Sengqiang

Human adenovirus (HAdV) pneumonia poses a major health burden for young children, however, factors that contribute to disease severity remain elusive. We analyzed immune cells from bronchoalveolar lavage (BAL) of children with HAdV pneumonia and found that CD19⁺CD21^low B cells were significantly enriched in the BAL and were associated with increased autoantibody concentrations and disease severity. Myeloid cells, PD-1⁺CD4⁺ T helper cells and CD21^low B cells formed tertiary lymphoid structures within the respiratory tracts. Myeloid cells promoted autoantibody production by expressing high amounts of B cell activating factor (BAFF). In contrast, PD-1⁺CD4⁺ T helper cells induced production of IgG1 and IgG3 antibodies but suppressed autoreactive IgGs by initiating B cell receptor editing. In summary, this study reveals cellular components involved in protective versus autoreactive immune pathways in the respiratory tract, and these findings provide potential therapeutic targets for severe HAdV lower respiratory tract infections.

News (Medical) associated with Adenovirus Infections, Human

12 Jul 2021

·www.nsmedicaldevices.com

QIAGEN’s NeuMoDx HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections

Important expansion of menu for NeuMoDx 96 and 288 Molecular Systems marks the 15th assay with a CE-IVD marking, one of the largest menus available for integrated PCR testing QIAGEN’s NeuMoDx HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections. (Credit: Belova59 from Pixabay) QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx™ HAdV Quant Assay for the identification and quantification of human adenovirus (HAdV) DNA has received CE-IVD certification for the European Union and other countries that accept this marking. This milestone marks the 15th assay available on the NeuMoDx™ 96 and 288 Molecular Systems, which is considered one of the broadest menus available among competitors. The tests can be run in true random access along with Laboratory Developed Tests (LDTs). Additional assays planned for CE-IVD launch in 2021 include Herpes Simplex Virus (HSV I/II), Human Herpesvirus 6 (HHV-6) as well as an FDA submission for Chlamydia & Gonorrhea (CT/NG). Testing for the human adenovirus is critical since it can cause severe respiratory and other diseases in patients with weakened immune systems, a common consequence of organ transplantation. The new HAdV Quant Assay was developed in partnership with Sentinel Diagnostics, an IVD company engaged in the development and production of diagnostic kits for Clinical Chemistry, Immunochemistry and Molecular Diagnostics. The availability of the HAdV assay strengthens the current NeuMoDx transplant assay menu that already includes CE-marked tests for cytomegalovirus (CMV), Epstein–Barr virus (EBV) and BK Virus (BKV) viral load monitoring for the management of immunocompromised patients, such as those who have undergone organ transplantation. All of these assays make use of QIAGEN’s automated, three-step NeuMoDx solutions that extract DNA from blood or urine to isolate the target nucleic acids and then conduct a real-time polymerase chain reaction (RT-PCR) to target conserved sequences in the HAdV genome. The NeuMoDx solutions currently offer CE-IVD tests for various viral and bacterial pathogens. Aside from assays for respiratory infections from SARS-CoV-2 to the 4-Plex test for Influenza A and B, RSV and SARS-CoV-2 covering the most common respiratory pathogens, there are tests for blood-borne viruses and post-transplant monitoring for CMV, EBV and BKV. The menu also features assays covering sexual and reproductive health including HPV and Chlamydia trachomatis. Source: Company Press Release

Collaborate

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Adenovirus Infections, Human

Basic Info

Related

Analysis